Theriva Biologics, Inc.
TOVX
$1.42
$0.00780.55%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -39.81% | -38.23% | -8.63% | 4.29% | 6.79% |
| Total Depreciation and Amortization | 1.48% | 23.14% | 30.97% | 43.43% | 58.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 354.06% | 1,314.99% | -71.53% | -333.22% | -333.46% |
| Change in Net Operating Assets | -68.56% | 82.62% | 389.25% | 384.64% | 386.48% |
| Cash from Operations | 10.84% | -5.41% | 7.76% | 7.70% | 0.45% |
| Capital Expenditure | 99.50% | 75.95% | -56.30% | -56.45% | -74.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 99.50% | 75.95% | -56.30% | -56.45% | 95.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 10.67% | 10.67% | 95.38% | 98.60% | 94.55% |
| Issuance of Common Stock | 150.70% | 160.45% | -11.73% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 49.37% | 6.47% | 6.47% | 49.37% |
| Cash from Financing | 779.36% | 434.33% | -79.24% | 211.66% | 132.38% |
| Foreign Exchange rate Adjustments | -300.00% | 217.54% | 141.05% | 62.11% | -3.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 37.79% | 23.69% | 1.98% | 13.59% | 26.86% |